Systematic Review

Age at Glaucoma Diagnosis in Germline Myocilin Mutation Patients: Associations with Polymorphisms in Protein Stabilities

Tarin Tanji , Emily Cohen, Darrick Shen, Chi Zhang, Fei Yu, Anne L. Coleman and Jie J. Zheng *

Stein Eye Institute, Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA; tarintaeko@gmail.com (T.T.); emilycohen96@gmail.com (E.C.); shendarrick821@gmail.com (D.S.); czhang@jsei.ucla.edu (C.Z.); fyu@ucla.edu (F.Y.); coleman@jsei.ucla.edu (A.L.C.)

Abstract: Glaucoma is the leading cause of irreversible blindness worldwide, with elevated intraocular pressure (IOP) as the only known modifiable risk factor. Trabecular meshwork (TM)-inducible myocilin (the MYOC gene) was the first to be identified and linked to juvenile and primary open-angle glaucoma. It has been suggested that mutations in the MYOC gene and the aggregation of mutant myocilin in the endoplasmic reticulum (ER) of TM may cause ER stress, resulting in a reduced outflow of aqueous humor and an increase in IOP. We selected 20 MYOC mutations with experimentally determined melting temperatures of mutated myocilin proteins. We included 40 published studies with at least one glaucoma patient with one of these 20 MYOC mutations and information on age at glaucoma diagnosis. Based on data from 458 patients, we found that a statistically significant but weak correlation was present between age and melting temperature based on various assumptions for age. We therefore conclude that genetic analysis of MYOC mutations alone cannot be used to accurately predict age at glaucoma diagnosis. However, it might be an important prognostic factor combined with other clinical factors for critical and early detection of glaucoma.

Keywords: trabecular meshwork; myocilin; intraocular pressure; endoplasmic reticulum stress

1. Introduction

Glaucoma is the leading cause of irreversible blindness and is characterized by optic nerve damage and retinal ganglion cell loss [1,2]. Glaucoma affects approximately 70 million people worldwide, and is projected to affect 111.8 million people by 2040 [3]. Risk factors include a family history of glaucoma, age, chronic steroid use, myopia, diabetes, and hypertension [4]. Primary open-angle glaucoma (POAG) accounts for 90 percent of glaucoma cases and is defined by an open anterior chamber angle and elevated intraocular pressure (IOP) [3,5,6]. IOP is a measurement of the aqueous humor produced by the ciliary bodies that is drained out through the trabecular meshwork (TM) and uveoscleral outflow [6]. The TM, located in the iridocorneal angle, is a specialized and dynamic tissue that regulates IOP [6,7]. Changes in the cellular signaling pathways and physical structure of TM may increase resistance to aqueous humor outflow, which can increase IOP [8]. Increased IOP may then damage the optic nerve and cause irreversible glaucomatous optic nerve damage and subsequent vision loss [2]. Visual outcomes of patients with glaucoma are time-dependent, so improving current diagnostic methods for earlier detection and treatment of glaucoma is critical for minimizing the progression of irreversible vision loss [1,4].

Genetic analysis of glaucomatous mutations may be helpful in the early detection of glaucoma. Myocilin (the MYOC gene) was the first protein to be identified and linked to both juvenile open-angle glaucoma (JOAG) and POAG [9]. Myocilin is expressed in the TM
tissues, and myocilin expression is more extensive in the TM of patients with POAG compared to those who do not have glaucomatous phenotypes [10–13]. However, the function of myocilin in POAG development remains unknown. Nevertheless, approximately 3% to 5% of the 70 million people affected by glaucoma have MYOC mutations [10,14]. The major component of the myocilin protein is a well-structured olfactomedin (OLF) domain, and more than 90% of glaucoma-related mutations are located in this domain [12,15]. Therefore, it has been suggested that MYOC mutations and the aggregation of mutant myocilin in the ER of TM may cause cell stress, resulting in reduced cell function, decreased outflow of aqueous humor, and increased IOP, a glaucoma risk factor [16–19]. Indeed, a transgenic mouse model with the MYOCY437H mutation, demonstrating chronic ER stress, was associated with elevated IOP and TM cell death; however, administration of the chemical chaperone phenylbutyric acid decreased both myocilin accumulation in the ER and ER stress [20]. The conjugate base of the same chemical chaperone, sodium phenylbutyrate, also relieved ER stress in a transgenic mouse model [21]. ER stress was also relieved by knocking down expression of mutant MYOC using CRISPR-Cas-9-based treatment [22].

The stability of a protein can be defined by the protein’s melting temperature—the temperature at which fifty percent of the tested protein is denatured. The melting temperatures of the wild-type and several glaucoma-associated mutated OLF domains of myocilin were experimentally determined [23,24]. Indeed, compared to the wild type, the myocilin mutants responsible for glaucoma do have lower melting temperatures. Moreover, a moderate correlation (correlation coefficient of 0.54) between the ages at glaucoma diagnosis of patients with MYOC mutations with the melting temperatures of the mutated myocilin OLF domains was identified [23], further suggesting that the ER stress associated with aggregation of mutant myocilin plays a key role in IOP elevation. However, this notion has been challenged. For example, the effects of the most common MYOC variant (p.Gln368Ter) on IOP in several large-scale population panels were studied, and the results of those studies are not consistent [25–27]. This mutant loses about half of the myocilin OLF domain, and the rest of the OLF is completely unfolded [23]. However, it was found that the penetrance of this mutation is relatively lower in different populations [26,27], although a later study suggests that the lower penetrance may be caused by underdiagnosis [28].

To further evaluate this issue, we decided to examine all the literature that reported on glaucoma patients with MYOC mutations and to assess the relationship between the melting temperature of mutated myocilin proteins and the age at glaucoma diagnosis of patients through a meta-analysis. A correlation between age at diagnosis of glaucoma and MYOC mutations can inform patients with these MYOC mutations whether they are at a higher risk of developing glaucoma before irreversible vision loss occurs. We confirmed the correlation between the melting temperatures of glaucoma-associated myocilin mutants and age at glaucoma diagnosis [23,24], but the correlation we obtained is weak. While this weak correlation would validate the notion that myocilin protein stability is associated with TM cell death due to ER stress, it may also suggest that other factors, such as environment and genetic background, may also play a role in glaucoma development [29]. Indeed, it is known that the prevalence of glaucoma increases with age [3,30].

2. Materials and Methods
2.1. Eligibility Criteria for Considering Studies

The study included melting temperatures of the wild-type myocilin protein and of 22 mutated myocilin proteins that have been experimentally measured. Nineteen of the mutants had lower melting temperatures than that of the wild-type and three mutants had higher melting temperatures [24]. Among those 22 MYOC mutations, we found 20 mutations on the myocilin.com website [15,31] associated with at least one glaucoma patient (the last search was on 1 May 2018). The 20 mutations include the 19 mutations that have lower melting temperatures than the wild-type and the K398R mutant that has a slightly higher melting temperature than the wild-type (Table 1 and Figure 1).
| MYOC          | MT * | N (Known + Unknown) ** | Frequency (%) |
|--------------|------|------------------------|---------------|
| K423E [29,32,33] | 34.2 | 13 (13 + 0)            | 2.84          |
| I477N [34–38]  | 37.7 | 66 (16 + 50)           | 14.41         |
| I477S [39]    | 39.7 | 20 (0 + 20)            | 4.37          |
| Y427H [40]    | 40.3 | 35 (1 + 34)            | 7.64          |
| C433R [41,42] | 40.4 | 20 (13 + 7)            | 4.37          |
| R272G [34]    | 41   | 5 (1 + 4)              | 1.09          |
| S502P [43]    | 41   | 8 (8 + 0)              | 1.75          |
| V426F [34,36,44] | 41.5 | 17 (5 + 12)            | 3.71          |
| N480K [39,45–49] | 42.4 | 47 (47 + 0)            | 10.26         |
| G246R [39]    | 42.5 | 7 (7 + 0)              | 1.53          |
| G367R [32,37,50–56] | 42.7 | 30 (30 + 0)            | 6.55          |
| I499F [39]    | 42.8 | 7 (7 + 0)              | 1.53          |
| G252R [34,36,37,50,57,58] | 43   | 23 (23 + 0)            | 5.02          |
| E323K [34,36] | 44   | 12 (1 + 11)            | 2.62          |
| T377M [34,35,37,40,51,59–65] | 44.3 | 100 (85 + 15)          | 21.83         |
| G364V [35]    | 45   | 22 (0 + 22)            | 4.80          |
| P481L [32]    | 45.5 | 1 (1 + 0)              | 0.22          |
| D380A [43,66] | 46.6 | 19 (19 + 0)            | 4.15          |
| A427T [67,68] | 48.3 | 2 (2 + 0)              | 0.44          |
| K398R [69,70] | 53.8 | 4 (4 + 0)              | 0.87          |

* MT: Melting Temperature. ** N (Known + Unknown): Number of patients (number of patients with known individual on set age + number of patients with unknown individual on set age). Total numbers 458 (283 + 175).

Figure 1. Cartoon structure of the OLF domain of myocilin. The amino acids with known mutations used for statistical analysis are shown as green balls.

Guided by the data present in myocilin.com [31] the literature was searched for publications from 1997 to 2018 that are associated with those 20 MYOC mutations. A total
of 80 publications were identified. Each publication was reviewed for at least one patient with a MYOC mutation and age at diagnosis of glaucoma, and a total of 40 articles (listed in the Supplemental Information) met the following inclusion criteria: contains at least one patient with a MYOC mutation with a glaucoma diagnosis. The primary study outcome was the age at glaucoma diagnosis of patients with one of these 20 MYOC mutations.

2.2. Data Synthesis and Analysis

Publications in myocilin.com [31] were identified from December 2017 to May 2018. Several publications only describe aggregate mean or median ages of diagnosis for a group of patients who carry the same MYOC mutation. The authors of those publications were contacted. Because of different reasons, we were still unable to obtain individual ages of diagnosis of some patients. Nevertheless, for all the patients whose ages at glaucoma diagnosis could not be extracted, we obtained a mean or median of onset of those patients and the number of individuals with the MYOC mutation. Therefore, our data was compiled and sorted into two categories: data of aggregate mean or median ages of diagnosis for a group of patients with a single mutation or individual ages of diagnosis for patients with a given mutation. To reconcile the two types of data, the correlation between age at diagnosis and melting temperature was examined by two different methods.

The first method was a hot-deck analysis of the summary data, where n number of individuals for each mean age reported in each publication were included in a regression analysis. The number n refers to the number of individuals included in the reported mean. The second method imputed n individual ages drawn randomly from a Gaussian distribution, assuming mean and standard deviation as reported in each publication. For publications that did not provide standard deviation, an approximation of standard deviation was calculated as the range (maximum age–minimum age) divided by 4. In addition, since some random age values might be out of the reported range due to randomly being drawn from a Gaussian distribution, the random age values were truncated to the reported range when available.

Finally, the imputed age from the two imputation methods were combined with the reported individual age values for all publications, and the Pearson correlation coefficient between age and melting temperature was calculated for both sets. The scatter plots with a fitted linear line were generated to illustrate the correlation.

3. Results

The experimentally determined melting temperatures of 20 myocilin mutations were obtained from Donegan et al. [24]. A total of 80 published studies were identified; 40 publications met the inclusion criterion: at least one patient carrying one of the 20 MYOC mutations, and information on glaucomatous phenotypes. From those publications, we extracted a total of 458 patients (Table 1); among them, the number of patients whose age at glaucoma diagnosis were available is 283. There were also 175 patients whose individual age at glaucoma diagnosis was unknown; only the summary statistics for age at diagnosis of these patients were known. These patients carried the following nine MYOC mutations (I477N, I477S, Y427H, C433R, R272G, V426F, E323K, T377M, G364V). In an attempt to include these patients in our statistical analysis, we used two different methods. In the first method, we used hot-deck imputation [71] to include 175 patients (Figure 2). In the second method, we imputed the individual ages of these patients as a random value drawn from a Gaussian distribution, assuming the mean and standard deviation as reported in each publication (Figure 3).
method, we used hot-deck imputation [71] to include 175 patients (Figure 2). In the second
include these patients in our statistical analysis, we used two different methods. In the first
of these patients were known. These patients carried the following nine
age at glaucoma diagnosis was unknown; only the summary statistics for age at diagnosis

glaucoma diagnosis were available is 283. There were also 175 patients whose individual
ttracted a total of 458 patients (Table 1); among them, the number of patients whose age at

correlation coefficient between age of diagnosis and melting temperature is 0.34489. Linear regres-
[maximum age–minimum age]/4 if SD was not give n) and truncated by the given range. Pearson

Regression of age of diagnosis (Age) on melting temperature (MT) is Age = -34.82 + 1.58×MT (p < 0.0001); R-squared = 0.142; n = 458.

Figure 2. Plot of age at diagnosis versus the respective myocilin melting temperatures. Known
individuals are blue; unknown individual ages at diagnosis are red. Pearson correlation coefficient
between age of diagnosis and melting temperature is 0.37626. Linear regression of age of diagnosis
(Age) on melting temperature (MT) is: Age = −38.05 + 1.65 × MT (p < 0.0001); R-squared = 0.142; n = 458.

Figure 3. Age at diagnosis vs melting temperature, using randomly generated data points according
to literature with summary statistics. Age for those with known individual ages (blue) and those
with unknown individual ages (red) whose ages were imputed by a value randomly drawn from a
Gaussian distribution with known mean age and standard deviation, SD, (SD was calculated as [maximum age–minimum age]/4 if SD was not given) and truncated by the given range. Pearson
correlation coefficient between age of diagnosis and melting temperature is 0.34489. Linear regression
of age of diagnosis (Age) on melting temperature (MT) is Age = −34.82 + 1.58 × MT (p < 0.0001); R-squared = 0.119; n = 458.
The analysis results of the two methods including: the Pearson correlation coefficient, linear regression model, and scatter plot between age and melting temperature, are shown in Figures 2 and 3. Similar results obtained from both methods of analysis gave us similar results. The correlation between age and melting temperature based on various assumptions for age (known individual age only or known individual age plus imputed age for those with unknown age) is statistically significant. The correlation coefficients calculated from both methods were 0.38 and 0.34, respectively, as evidenced by the wide range of age distribution at each melting temperature shown in the scatter plots, especially for the middle range of melting temperature (38 degrees to 45 degrees).

4. Discussion

ER stress implicated in ocular diseases including glaucoma and neurodegenerative diseases [17,72] can be induced by genetic mutations, overexpression of genes, or other pathophysiological processes that lead to protein aggregation in the ER lumen [73]. When large quantities of the misfolded myocilin aggregate in the ER lumen, the unfolded protein response (UPR) pathway can induce cell death [74,75]. Our analysis shows there is a weak to moderate correlation between the stability of mutated myocilin and age at glaucoma diagnosis of those patients who have the mutations. This is consistent with the hypothesis of the ER stress mechanism in glaucomatous TM [18,19,76].

Myocilin is overexpressed in TM cells, and its expression can be further enhanced by factors such as aging, mechanical stress, and steroid treatment. In a clinical setting, glucocorticoids are commonly used to treat postoperative inflammation, but may lead to steroid-induced ocular hypertension (SIOH) and steroid-induced glaucoma (SIG) [77]. However, it is unclear whether myocilin increases the risk of SIOH or SIG [77]. Treatment of one type of glucocorticoid, dexamethasone, was found to induce a significant increase in myocilin in cultured human TM cells, explants, and perfusion-cultured cells [78,79]; the range of induction (fold increase) of myocilin was 0.9–20 [78]. On the other hand, dexamethasone treatment resulted in a range of IOP increases and significant increases of at least 21 mmHg among only 30 percent of the participants [80]. It is likely that the dexamethasone-related IOP increase is connected to the dexamethasone-induced increase in myocilin protein expression [81]. Therefore, for those patients who carry MYOC missense mutations, myocilin overexpression may lead to additional ER stress and cell death [2,18,77].

However, ER-stress-induced URP can not only trigger cell death, but can also stimulate ER-associated protein degradation (ERAD) to prevent cell death [75,82]. The two opposite effects induced by ER stress, combined with the natural variation of myocilin production in the general population, may explain why there is a weak correlation between protein stability of mutated myocilin and age of glaucoma diagnosis. In our study, while we confirmed the positive correlation, the correlation we obtained is much weaker than what was reported previously, which is based on a limited data set [23]. Our study indicates that although many individuals with MYOC mutations have ER stress in the TM, not every individual with an MYOC mutation will respond with a stress-induced, high-fold increase in myocilin expression and develop myocilin-associated glaucoma [83]. This may be due to possible moderating variables, including varying patient environments and different genetic components. Indeed, it has been shown that diet, exercise routine, and patient lifestyle may affect IOP and influence POAG development [84–86]. For example, smoking and consuming coffee may increase IOP, while engaging in general physical exercise may decrease IOP [86,87]. Data from the National Health and Nutrition Examination Survey found that adult participants aged 40 years and older who performed moderate amounts of vigorous activity had 95% decreased odds of developing glaucoma compared to those who did not perform vigorous activity [86]. In the context of URP-mediated TM disruption, exercise reducing the prevalence of glaucoma could make sense, as exercise is shown to reduce oxidative stress and reverse age-related ER and mitochondrial dysfunction [88].
Despite weak variables, this correlation may be an important prognostic factor for the early detection of glaucoma and may be useful to future understanding of genetic tools in clinical care. The slopes calculated from the two methods are very similar in the linear relationship between age of diagnosis and the mutants’ melting temperature (1.58 obtained from the first method and 1.65 from the second method). If we take the average of the two values, 1.62, as the result of our study, this means that every degree decrease in melting temperature due to mutation lowers the age of diagnosis by 1.62 years. Glaucoma often begins asymptomatically [84,89], so it is critical to diagnose patients early before irreversible vision loss has already occurred. Equipped with such knowledge, physicians can more accurately determine which patients require increased screening for early detection of glaucoma, which is particularly critical for pediatric patients. Physicians could screen for patients with a family history of glaucoma and refer them for genetic testing at a clinical laboratory that meets the Clinical Labs Information Act standards. The presence of MYOC mutations would be clinically instructive for patients’ glaucoma treatment plans. Patients with MYOC mutations would undergo increased surveillance to detect any signs of glaucoma as early as possible, rather than the usual standard of eye care. The results of our study provide knowledge for patients with MYOC mutations concerning their risk for developing glaucoma in the future and may minimize irreversible vision loss through increased screening for patients at risk for glaucoma diagnosis.

Finally, other than the 20 MYOC mutations we examined in this study, there are many more known MYOC mutations that have been implicated in glaucoma [12,13]. It is likely that most of these mutations, if not all, are less stable than the wild-type myocilin, and that they cause ER stress in TM cells similar to the 20 mutations examined in this study [17,18]. Therefore, the correlations between the stabilities of these mutated myocilin proteins and age at glaucoma diagnosis of patients who carry the mutations should be similar as well. Further biophysical studies of the thermostability of those myocilin mutants, together with accurate genomic testing, will provide us with valuable information for glaucoma prevention and treatment.

Author Contributions: Conceptualization, J.J.Z.; methodology, T.T., E.C., D.S. and F.Y.; software, C.Z.; validation, T.T. and E.C.; formal analysis, D.S. and F.Y.; investigation, T.T. and E.C.; data curation, T.T. and E.C.; writing—original draft preparation, T.T. and E.C.; writing—review and editing, J.J.Z.; supervision, F.Y., A.L.C. and J.J.Z.; project administration, J.J.Z.; funding acquisition, A.L.C. and J.J.Z. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported in part by NIH grants R01EY028557 and 5P30EY000331, and by Research to Prevent Blindness.

Institutional Review Board Statement: This systematic review does not require Institutional Review Board approval.

Informed Consent Statement: Only published data are reviewed, and no information has been obtained directly from patients.

Data Availability Statement: All the data obtained in the study are presented.

Acknowledgments: We would like to thank members of J.J.Z. lab for helpful discussions.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Quigley, H.A. Glaucoma. *Lancet* 2011, 377, 1367–1377. [CrossRef]
2. Caprioli, J. Glaucoma: A disease of early cellular senescence. *Investig. Ophthalmol. Vis. Sci.* 2013, 54, ORSF60–ORSF67. [CrossRef] [PubMed]
3. Tham, Y.C.; Li, X.; Wong, T.Y.; Quigley, H.A.; Aung, T.; Cheng, C.Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. *Ophthalmology* 2014, 121, 2081–2090. [CrossRef] [PubMed]
4. McMonnies, C.W. Glaucoma history and risk factors. *J. Optom.* 2017, 10, 71–78. [CrossRef] [PubMed]
5. Kwon, Y.H.; Fingert, J.H.; Kuehn, M.H.; Alward, W.L. Primary open-angle glaucoma. *N. Engl. J. Med.* 2009, 360, 1113–1124. [CrossRef] [PubMed]
6. Braunger, B.M.; Fuchshofer, R.; Tamm, E.R. The aqueous humor outflow pathways in glaucoma: A unifying concept of disease mechanisms and causative treatment. *Eur. J. Pharm. Biopharm.* 2013, 89, 173–181. [CrossRef] [PubMed]

7. Vranka, J.A.; Kelley, M.J.; Acott, T.S.; Kellner, K.E. Extracellular matrix in the trabecular meshwork: Intraocular pressure regulation and dysregulation in glaucoma. *Exp. Eye Res.* 2015, 133, 112–125. [CrossRef] [PubMed]

8. Tektas, O.Y.; Lutjen-Drecoll, E. Structural changes of the trabecular meshwork in different kinds of glaucoma. *Exp. Eye Res.* 2009, 88, 769–775. [CrossRef]

9. Stone, E.M.; Fingert, J.H.; Alward, W.L.; Nguyen, T.D.; Polansky, J.R.; Sunden, S.L.; Nishimura, D.; Clark, A.F.; Nystuen, A.; Nichols, B.E.; et al. Identification of a gene that causes primary open angle glaucoma. *Science* 1997, 275, 668–670. [CrossRef] [PubMed]

10. Fingert, J.H.; Stone, E.M.; Sheffied, V.C.; Alward, W.L. Myocilin glaucoma. *Surv. Ophthalmol.* 2002, 47, 547–561. [CrossRef] [PubMed]

11. Gong, G.; Kosoko-Lasaki, O.; Haynatzki, G.R.; Wilson, M.R. Genetic dissection of myocilin glaucoma. *Hum. Mol. Genet.* 2004, 13, R91–R102. [CrossRef] [PubMed]

12. Resch, Z.T.; Fautsch, M.P. Glaucoma-associated myocilin: A better understanding but much more to learn. *Exp. Eye Res.* 2009, 88, 704–712. [CrossRef] [PubMed]

13. Borras, T. The effects of myocilin expression on functionally relevant trabecular meshwork genes: A mini-review. *J. Ocul. Pharmacol. Ther.* 2014, 30, 202–212. [CrossRef] [PubMed]

14. Patterson-Orazem, A.C.; Lieberman, R.L. Antibodies used to detect glaucoma-associated myocilin: More or less than meets the eye? *Investig. Ophthalmol. Vis. Sci.* 2019, 60, 2034–2037. [CrossRef] [PubMed]

15. Hewitt, A.W.; Mackey, D.A.; Craig, J.E. Myocilin allele-specific glaucoma phenotype database. *Hum. Mutat.* 2008, 29, 207–211. [CrossRef] [PubMed]

16. Polansky, J.R.; Fauss, D.J.; Zimmerman, C.C. Regulation of tigr/myoc gene expression in human trabecular meshwork cells. *Eye* 2000, 14B Pt 3, 503–514. [CrossRef] [PubMed]

17. Anholt, R.R.; Carbone, M.A. A molecular mechanism for glaucoma: Endoplasmic reticulum stress and the unfolded protein response. *Trends Mol. Med.* 2013, 19, 586–593. [CrossRef] [PubMed]

18. Stothert, A.R.; Fontaine, S.N.; Sabbagh, J.J.; Dickey, C.A. Targeting the eR-autophagy system in the trabecular meshwork to treat glaucoma. *Exp. Eye Res.* 2016, 144, 38–45. [CrossRef] [PubMed]

19. Sears, N.C.; Boese, E.A.; Miller, M.A.; Fingert, J.H. Mendelian genes in primary open angle glaucoma. *Exp. Eye Res.* 2019, 186, 107702. [CrossRef] [PubMed]

20. Zode, G.S.; Kuehn, M.H.; Nishimura, D.Y.; Sears, C.C.; Mohan, K.; Grozdanic, S.D.; Bugge, K.; Anderson, M.G.; Clark, A.F.; Stone, E.M.; et al. Reduction of er stress via a chemical chaperone prevents disease phenotypes in a mouse model of primary open angle glaucoma. *J. Clin. Investig.* 2011, 121, 3542–3553. [CrossRef] [PubMed]

21. Zode, G.S.; Bugge, K.E.; Mohan, K.; Grozdanic, S.D.; Peters, J.C.; Koehn, D.R.; Anderson, M.G.; Kardon, R.H.; Stone, E.M.; Sheffield, V.C. Topical ocular sodium 4-phenylbutyrate rescues glaucoma in a myocilin mouse model of primary open-angle glaucoma. *Investig. Ophthalmol. Vis. Sci.* 2012, 53, 1557–1565. [CrossRef] [PubMed]

22. Jain, A.; Zode, G.; Kasetti, R.B.; Ran, F.A.; Yan, W.; Sharma, T.P.; Bugge, K.; Sears, C.C.; Fingert, J.H.; Zhang, F.; et al. Crispr-cas9-based treatment of myocilin-associated glaucoma. *Proc. Natl. Acad. Sci. USA* 2017, 114, 11199–11204. [CrossRef] [PubMed]

23. Burns, J.N.; Turnage, K.C.; Walker, C.A.; Lieberman, R.L. The stability of myocilin olfactomedin domain variants provides new insight into glaucoma as a protein misfolding disorder. *Biochemistry* 2011, 50, 5824–5833. [CrossRef] [PubMed]

24. Donegan, R.K.; Hill, S.E.; Freeman, D.M.; Nguyen, E.; Orwig, S.D.; Turnage, K.C.; Lieberman, R.L. Structural basis for misfolding in myocilin-associated glaucoma. *Hum. Mol. Genet.* 2015, 24, 2111–2124. [CrossRef] [PubMed]

25. Souzeau, E.; Uitterlinden, A.G.; Healey, P.R.; Goldberg, I.; Mackay, D.A.; Hewitt, A.W.; Burdon, K.P.; et al. Myocilin predictive genetic testing for primary open-angle glaucoma leads to early identification of at-risk individuals. *Ophthalmology* 2017, 124, 303–309. [CrossRef] [PubMed]

26. Nag, A.; Lu, H.; Arno, M.; Iglesias, A.I.; Bonnenmaier, P.; Broer, L.; Uitterlinden, A.G.; Klaver, C.C.; van Duijn, C.; Hysi, P.G.; et al. Evaluation of the myocilin mutation gln368stop demonstrates reduced penetrance for glaucoma in European populations. *Ophthalmology* 2017, 124, 547–553. [CrossRef] [PubMed]

27. Han, X.; Souzeau, E.; Ong, J.S.; An, J.; Siggs, O.M.; Burdon, K.P.; Best, S.; Goldberg, I.; Healey, P.R.; Graham, S.L.; et al. Myocilin gene gln368ter variant penetrance and association with glaucoma in population-based and family-based studies. *JAMA Ophthalmol.* 2019, 137, 28–35. [CrossRef] [PubMed]

28. Zebardast, N.; Sekimitsu, S.; Wang, J.; Elze, T.; Gharakhkhani, P.; Cole, B.S.; Lin, M.M.; Segre, A.V.; Wiggs, J.L.; International Glaucoma Genetics Consortium. Characteristics of p.Gln368ter myocilin variant and influence of polygenic risk on glaucoma penetrance in the uk biobank. *Ophthalmology* 2021, 128, 1300–1311. [CrossRef] [PubMed]

29. Morisette, J.; Clepet, C.; Moisan, S.; Dubois, S.; Winstead, E.; Vermeerden, D.; Nguyen, T.D.; Polansky, J.R.; Cote, G.; Anctil, J.L.; et al. Homozygotes carrying an autosomal dominant tigr mutation do not manifest glaucoma. *Nat. Genet.* 1998, 19, 319–321. [CrossRef] [PubMed]

30. Cedrone, C.; Mancino, R.; Cerulli, A.; Cesareo, M.; Nucci, C. Epidemiology of primary glaucoma: Prevalence, incidence, and blinding effects. *Prog. Brain Res.* 2008, 173, 3–14. [CrossRef] [PubMed]
31. The myocilin.com Allele Specific Phenotype Database. Available online: http://www.myocilin.com/index.php (accessed on 11 November 2021).

32. Faucher, M.; Ancil, J.L.; Rodrigue, M.A.; Duchesne, A.; Bergeron, D.; Blondeau, P.; Cote, G.; Dubois, S.; Bergeron, J.; Arseneault, R.; et al. Founder tigr/myocilin mutations for glaucoma in the quebec population. Hum. Mol. Genet. 2002, 11, 2077–2090. [CrossRef] [PubMed]

33. Bruttini, M.; Longo, I.; Frezzotti, P.; Ciapetta, R.; Randazzo, A.; Orzalesi, N.; Fumagalli, E.; Caporossi, A.; Frezzotti, R.; Renieri, A. Mutations in the myocilin gene in families with primary open-angle glaucoma and juvenile open-angle glaucoma. Arch. Ophthalmol. 2003, 121, 1034–1038. [CrossRef] [PubMed]

34. Shimizu, S.; Lichter, P.R.; Johnson, A.T.; Zhou, Z.; Higashi, M.; Gottfredsdottir, M.; Othman, M.; Moroi, S.E.; Rozsa, F.W.; Schertzer, R.M.; et al. Age-dependent prevalence of mutations at the glc1a locus in primary open-angle glaucoma. Am. J. Ophthalmol. 2000, 130, 165–177. [CrossRef]

35. Alward, W.L.; Fingert, J.H.; Coote, M.A.; Johnson, A.T.; Lerner, S.F.; Junqua, D.; Durcan, F.J.; McCartney, P.J.; Mackey, D.A.; Sheffield, V.C.; et al. Clinical features associated with mutations in the chromosome 1 open-angle glaucoma gene (gla). N. Engl. J. Med. 1998, 338, 1022–1027. [CrossRef] [PubMed]

36. Rozsa, F.W.; Shimizu, S.; Lichter, P.R.; Johnson, A.T.; Othman, M.I.; Scott, K.; Downs, C.A.; Nguyen, T.D.; Polansky, J.; Richards, J.E. Glc1a mutations point to regions of potential functional importance on the tigr/myoc protein. Mol. Vis. 1998, 4, 20. [PubMed]

37. Souzeau, E.; Burdon, K.P.; Dubowsky, A.; Grist, S.; Usher, B.; Fitzgerald, J.T.; Crawford, A.; Hewitt, A.W.; Goldberg, I.; Mills, R.A.; et al. Higher prevalence of myocilin mutations in advanced glaucoma in comparison with less advanced disease in an australasian disease registry. Ophthalmology 2013, 120, 1135–1143. [CrossRef] [PubMed]

38. Richards, J.E.; Ritch, R.; Lichter, P.R.; Rozsa, F.W.; Stringham, H.M.; Caronia, R.M.; Johnson, D.; Abundo, G.P.; Willcockson, J.; Downs, C.A.; et al. Novel trabecular meshwork inducible glucocorticoid response mutation in an eight-generation juvenile-onset primary open-angle glaucoma pedigree. Ophthalmology 1998, 105, 1698–1707. [CrossRef]

39. Adam, M.F.; Belmouden, A.; Binisti, P.; Brezin, A.P.; Valtot, F.; Bechetoille, A.; Dascotte, J.C.; Copin, B.; Gomez, L.; Chaventre, A.; et al. Recurrent mutations in a single gla exon linking the evolutionarily conserved olfactomedin-homology domain of tigr in familial open-angle glaucoma. Hum. Mol. Genet. 1997, 6, 2091–2097. [CrossRef] [PubMed]

40. Wiggs, J.L.; Allingham, R.R.; Vollrath, D.; Jones, K.H.; de la Paz, M.; Kern, J.; Patterson, K.; Babb, V.L.; del Bono, E.A.; Broomer, B.W.; et al. Prevalence of mutations in tigr/myocilin in patients with adult and juvenile primary open-angle glaucoma. Am. J. Hum. Genet. 1998, 63, 1549–1552. [CrossRef]

41. Povoa, C.A.; Malta, R.F.; Mde, M.R.; de Melo, K.F.; Giannella-Neto, D. Correlation between genotype and phenotype in primary open angle glaucoma of brazilian families with mutations in exon 3 of the tigr/myoc gene. Arq. Bras. Oftalmol. 2006, 69, 289–297. [CrossRef]

42. Vasconcellos, J.P.; Melo, M.B.; Costa, V.P.; Tsukumo, D.M.; Basseres, D.S.; Bordin, S.; Saad, S.T.; Costa, F.F. Novel mutation in the myocilin gene in primary open glaucoma patients. J. Med. Genet. 2000, 37, 301–303. [CrossRef] [PubMed]

43. Stolova, D.; Child, A.; Brice, G.; Desai, T.; Barsoum-Homsy, M.; Ozdemir, N.; Chevrette, L.; Adam, M.F.; Garchon, H.J.; Crick, R.P.; et al. Novel tigr/myoc mutations in families with juvenile-onset primary open angle glaucoma. J. Med. Genet. 1998, 35, 989–992. [CrossRef] [PubMed]

44. Lim, P.; Lichter, P.R.; Higashi, M.; Downs, C.A.; Richards, J.E. Septuagenarian’s phenotype leads to ascertainment of familial myocilin mutation. J. Glaucoma 2002, 12, 98–103. [CrossRef]

45. Souzeau, E.; Goldberg, I.; Healey, PR.; Mills, R.A.; Landers, J.; Graham, S.L.; Grigg, J.R.; Usher, B.; Straga, T.; Crawford, A.; et al. Australian and new zealand registry of advanced glaucoma: Methodology and recruitment. Clin. Exp. Ophthalmol. 2012, 40, 569–575. [CrossRef]

46. Brezin, A.P.; Adam, M.F.; Belmouden, A.; Lureau, M.A.; Chaventre, A.; Copin, B.; Gomez, L.; de Dinechin, S.D.; Berkani, M.; Valtot, F.; et al. Founder effect in glc1a-linked familial open-angle glaucoma in northern france. Am. J. Med. Genet. 1998, 76, 438–445. [CrossRef]

47. Mimivati, Z.; Nurilza, K.; Marini, M.; Liza-Sharmini, A. Identification of myocilin gene mutation and polymorphism in a large malay family with juvenile-onset open angle glaucoma. Mol. Vis. 2010, 16, 714–723. [PubMed]

48. Hulsman, C.A.; de Jong, PT.; Lettinink, M.; van Duijn, C.M.; Hofman, A.; Bergen, A.A. Myocilin mutations in a population-based sample of cases with open-angle glaucoma: The rotterdam study. Graefes. Arch. Clin. Exp. Ophthalmol. 2002, 240, 468–474. [CrossRef] [PubMed]

49. Guevara-Fujita, M.L.; Perez-Grossmann, R.A.; Estrada-Cuzcano, A.; Pawar, H.; Vargas, E.; Richards, J.E.; Fujita, R. Recurrent myocilin asn480lys glaucoma causative mutation arises de novo in a family of andean descent. J. Glaucoma 2008, 17, 67–72. [CrossRef] [PubMed]

50. Vincent, A.L.; Billingsley, G.; Buys, Y.; Levin, A.V.; Priston, M.; Trope, G.; Williams-Lyn, D.; Heon, E. Digenic inheritance of early-onset glaucoma: Cyp1b1, a potential modifier gene. Am. J. Hum. Genet. 2002, 70, 448–460. [CrossRef] [PubMed]

51. Kanagavalli, J.; Krishnadas, S.R.; Pandaranayaka, E.; Krishnaswamy, S.; Sundaresan, P. Evaluation and understanding of myocilin mutations in indian primary open angle glaucoma patients. Mol. Vis. 2003, 9, 606–614. [CrossRef] [PubMed]

52. Iliev, M.E.; Bodmer, S.; Gallati, S.; Lanz, R.; Sturmer, J.; Katsoulis, K.; Wolf, S.; Trittibach, P.; Sarra, G.M. Glaucoma phenotype in a large swiss pedigree with the myocilin gly367arg mutation. Eye 2008, 22, 880–888. [CrossRef] [PubMed]
78. Clark, A.F.; Steely, H.T.; Dickerson, J.E., Jr.; English-Wright, S.; Stropki, K.; McCartney, M.D.; Jacobson, N.; Shepard, A.R.; Clark, J.I.; Matsushima, H.; et al. Glucocorticoid induction of the glaucoma gene myoc in human and monkey trabecular meshwork cells and tissues. *Investig. Ophthalmol. Vis. Sci.* 2001, 42, 1769–1780.

79. Yun, A.J.; Murphy, C.G.; Polansky, J.R.; Newsome, D.A.; Alvarado, J.A. Proteins secreted by human trabecular cells. Glucocorticoid and other effects. *Investig. Ophthalmol. Vis. Sci.* 1989, 30, 2012–2022.

80. Becker, B.; Mills, D.W. Corticosteroids and intraocular pressure. *Arch. Ophthalmol.* 1963, 70, 500–507. [CrossRef] [PubMed]

81. Mao, W.; Tovar-Vidales, T.; Yorio, T.; Wordinger, R.J.; Clark, A.F. Perfusion-cultured bovine anterior segments as an ex vivo model for studying glucocorticoid-induced ocular hypertension and glaucoma. *Investig. Ophthalmol. Vis. Sci.* 2011, 52, 8068–8075. [CrossRef] [PubMed]

82. Green, D.R.; Galluzzi, L.; Kroemer, G. Cell biology. Metabolic control of cell death. *Science* 2014, 345, 1250256. [CrossRef] [PubMed]

83. Fingert, J.H. Penetrance of myocilin mutations-who gets glaucoma? *JAMA Ophthalmol.* 2019, 137, 35–37. [CrossRef] [PubMed]

84. Coleman, A.L.; Kodjebacheva, G. Risk factors for glaucoma needing more attention. *Open Ophthalmol. J.* 2009, 3, 38–42. [CrossRef] [PubMed]

85. Tseng, V.L.; Lee, J.; Yu, F.; Sirsy, O.; Coleman, A.L. Associations between factors related to atopic disease and glaucoma in the national health and nutrition examination survey. *Eur. J. Ophthalmol.* 2018, 28, 598–606. [CrossRef] [PubMed]

86. Tseng, V.L.; Yu, F.; Coleman, A.L. Association between exercise intensity and glaucoma in the national health and nutrition examination survey. *Ophthalmol. Glaucoma* 2020, 3, 393–402. [CrossRef] [PubMed]

87. Wiggs, J.L. The cell and molecular biology of complex forms of glaucoma: Updates on genetic, environmental, and epigenetic risk factors. *Investig. Ophthalmol. Vis. Sci.* 2012, 53, 2467–2469. [CrossRef]

88. Estebanez, B.; de Paz, J.A.; Cuevas, M.J.; Gonzalez-Gallego, J. Endoplasmic reticulum unfolded protein response, aging and exercise: An update. *Front. Physiol.* 2018, 9, 1744. [CrossRef] [PubMed]

89. Weinreb, R.N.; Aung, T.; Medeiros, F.A. The pathophysiology and treatment of glaucoma: A review. *JAMA* 2014, 311, 1901–1911. [CrossRef] [PubMed]